GSK's largest acquisition in recent years, a $10.6 billion purchase of cancer drug developer Nuvalent, signifies a new ...

GSK plc on Tuesday agreed to acquire Boston-based biotech firm Nuvalent, Inc. for $10.6 billion in cash as the British ...

By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer ...

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year ...

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s ...

British pharmaceutical giant GSK has announced its acquisition of Nuvalent, a U.S.-listed cancer drug developer, for $10.6 ...

GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday. The final USD10.6 ...

British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug ...

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...

Just 6 months into the job, GSK’s CEO is spearheading some big moves. The London-based pharma giant announced Tuesday that it ...

BRITISH drugmaker GSK on Tuesday agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion to boost its ...